Risk of coronary heart disease in patients with HIV infection (Q38261508)

1 September 2017

1 reference

title

Risk of coronary heart disease in patients with HIV infection (English)

1 reference

1 September 2017

0 references

1 reference

coronary artery disease

1 reference

4

Peter Reiss

1 reference

1 September 2017

1

Markella V Zanni

1 reference

1 September 2017

Judith Schouten

2

1 reference

PubMed ID

25331088

1 September 2017

Steven K Grinspoon

series ordinal

3

1 reference

PubMed ID

25331088

1 September 2017

language of work or name

English

0 references

publication date

21 October 2014

1 reference

Nature Reviews Cardiology

1 September 2017

1 reference

1 September 2017

11

1 reference

1 September 2017

728-741

1 reference

1 September 2017

12

1 reference

HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group

1 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Management of human immunodeficiency virus infection in advanced age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Ageing with HIV in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV and Africa's elderly: the problems and possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV infection and the risk of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Sudden cardiac death in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV infection and incidence of ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV and the heart: the impact of antiretroviral therapy: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

The prevalence of smoking and the knowledge of smoking hazards and smoking cessation strategies among HIV- positive patients in Johannesburg, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Deteriorating renal function and clinical outcomes in HIV-positive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Renal issues in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Body composition and metabolic changes in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Management of the metabolic effects of HIV and HIV drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased aldosterone among HIV-infected women with visceral fat accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV infection and the risk of diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

The metabolic effects of lopinavir/ritonavir in HIV-negative men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Differences between HIV-infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Elevated triglycerides and risk of myocardial infarction in HIV-positive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Kidney function and the risk of cardiovascular events in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Human immunodeficiency virus per se exerts atherogenic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Microbial translocation in HIV infection: causes, consequences and treatment opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Immune activation and HIV persistence: considerations for novel therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Abacavir and cardiovascular risk: reviewing the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Acute coronary syndromes in treatment-naïve black South africans with human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV and coronary heart disease: time for a better understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Associations between HIV infection and subclinical coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Arterial inflammation in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Epicardial fat is associated with duration of antiretroviral therapy and coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Cardiac complications of cocaine abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Human immunodeficiency virus 1 infection, cocaine, and coronary calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

A pilot study of screening, brief intervention, and referral for treatment (SBIRT) in non-treatment seeking smokers with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Impact of HIV infection and HAART on serum lipids in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV infects glomerular endothelial and mesangial but not epithelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV gp120 induces endothelial dysfunction in tumour necrosis factor-alpha-activated porcine and human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV envelope protein gp120-induced apoptosis in lung microvascular endothelial cells by concerted upregulation of EMAP II and its receptor, CXCR3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Human immunodeficiency virus type 1 (HIV-1) Nef activates STAT3 in primary human monocyte/macrophages through the release of soluble factors: involvement of Nef domains interacting with the cell endocytotic machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Human immunodeficiency virus impairs reverse cholesterol transport from macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV-1 Nef-mediated inhibition of T cell migration and its molecular determinants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Transfer of intracellular HIV Nef to endothelium causes endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF-beta 1 mRNA expression and protein synthesis in peripheral blood monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV-1 Tat protein binds to TLR4-MD2 and signals to induce TNF-α and IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV Tat induces expression of ICAM-1 in HUVECs: implications for miR-221/-222 in HIV-associated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV-1 Tat protein-induced VCAM-1 expression in human pulmonary artery endothelial cells and its signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Efavirenz induces interactions between leucocytes and endothelium through the activation of Mac-1 and gp150,95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased CD11/CD18 expression on the peripheral blood leucocytes of patients with HIV disease: relationship to disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell Turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Platelet count kinetics following interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Associations between immune depression and cardiovascular events in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Plasma levels of soluble CD14 independently predict mortality in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Association of C-reactive protein and HIV infection with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Atherosclerosis in Patients Infected With HIV Is Influenced by a Mutant Monocyte Chemoattractant Protein-1 Allele

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCR4 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Altered release of regulated upon activation, normal T-cell expressed and secreted protein from human, normal platelets: contribution of distinct HIV-1MN gp41 peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.167

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome

31 March 2020

1 reference

12 December 2020

Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression.

1 reference

12 December 2020

Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection

1 reference

12 December 2020

HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes.

1 reference

12 December 2020

Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.

1 reference

12 December 2020

Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells

1 reference

12 December 2020

Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1.

1 reference

12 December 2020

Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells

1 reference

12 December 2020

Human immunodeficiency virus type 1 (HIV-1) tat-protein stimulates the production of interleukin-6 (IL-6) by peripheral blood monocytes.

1 reference

12 December 2020

10.1038/NRCARDIO.2014.167

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25331088